Preclinical research further suggests that the addition of the CD8α receptor to an affinity-enhanced HLA class I-restricted TCR against MAGE-A4 can enhance CD4+ T helper and effector functions which could improve the depth and durability of anti-tumor immune responses.215. Here, MAGEA4 is linked to neoplasm.